<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517257</url>
  </required_header>
  <id_info>
    <org_study_id>NRA2580025</org_study_id>
    <nct_id>NCT00517257</nct_id>
  </id_info>
  <brief_title>Atorvastatin for the Treatment of Retinal Vein Occlusion</brief_title>
  <acronym>ATORVO</acronym>
  <official_title>Atorvastatin Toronto Retinal Vein Occlusion Study (ATORVO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Heart Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ontario Association of Optometrists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Toronto Ophthalmological Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ATORVO study is designed to determine whether atorvastatin (Lipitor) can improve vision,
      when compared to placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinal vein occlusion (RVO), a common cause of visual loss in the Western world, is a
      disease whose etiology resembles that of classic atherosclerosis. A therapy that lowers the
      risk of arterial and venous thrombosis would seem to be a reasonable approach to managing
      this disease, for which there is currently no treatment.

      ATORVO is a randomized double-masked clinical trial comparing a daily dose of 80 mg of
      atorvastatin to matched placebo in persons recently diagnosed with RVO. At 24 weeks after
      randomization, we will evaluate each participant's visual acuity and the presence of
      secondary complications related to RVO.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in improvement of at least 15 letters (3 lines) in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity in the affected eye at 24 weeks in patients on active treatment vs. placebo.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of ocular neovascularization or need for laser treatment by 24 weeks.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in macular edema, measured by optical coherence tomography at 24 weeks.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in The National Eye Institute 25-Item Visual Function Questionnaire-25 (VFQ-25) score from 0 to 24 weeks.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of non-fatal myocardial infarction, hospitalization for acute coronary syndrome, receipt of coronary revascularization, stroke or death, by 52 weeks.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the concentration of serum total cholesterol, LDL-cholesterol and highly sensitive C-reactive protein at 0 and 24 weeks.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Retinal Vein Thrombosis</condition>
  <condition>Central Retinal Vein Occlusion</condition>
  <condition>Branch Retinal Vein Occlusion</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 80 mg orally once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet orally once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80 mg orally once daily for 24 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet orally once daily for 24 weeks</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 40 years and older

          -  Diagnosed with CRVO or BRVO

          -  Visual acuity of 20/40 or worse in the affected eye

          -  Onset of current symptoms of loss of vision within the past 60 days

          -  Ability to understand spoken English

        Exclusion Criteria:

          -  Current use of a statin or fibrate medication

          -  Known cardiovascular disease or revascularization, including coronary artery disease
             (myocardial infarction or angina), stroke or peripheral artery occlusion

          -  Known diabetes mellitus

          -  Known liver disease

          -  Serum low-density lipoprotein cholesterol (LDL-C) &gt; 5.0 mmol/L

          -  Baseline serum triglycerides &gt; 6.0 mmol/L

          -  Serum ALT above 115 U/L (i.e., 2.5 x upper limit of normal)

          -  Baseline serum creatinine &gt; 250 Âµmol/L

          -  Ocular surgery within the past 90 days

          -  Planned ocular or cataract surgery within the study period

          -  Known retinal disease: age-related macular degeneration, retinal detachment or macular
             hole, or past history of vein occlusion

          -  Women who are pregnant or who are breastfeeding

          -  Participation in another clinical trial concurrently or within 30 days prior to
             screening

          -  Known allergy to fluorescein dye

          -  Current use of cyclosporine medication.

          -  Current use of an HIV protease inhibitor medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel G Ray, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigita Zile Zile, RN</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>4130</phone_ext>
    <email>zileb@smh.toronto.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joel Ray, MD MSc</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>6752</phone_ext>
    <email>rayj@smh.toronto.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigita Zile, RN CCRP</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>4130</phone_ext>
      <email>zileb@smh.toronto.on.ca</email>
    </contact>
    <investigator>
      <last_name>Joel G Ray, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David T Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Larry Leiter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaun Goodman, MD MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anatoly Langer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2007</study_first_posted>
  <last_update_submitted>June 23, 2008</last_update_submitted>
  <last_update_submitted_qc>June 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2008</last_update_posted>
  <keyword>Retinal vein occlusion</keyword>
  <keyword>Retinal vein thrombosis</keyword>
  <keyword>Central retinal vein occlusion</keyword>
  <keyword>Branch retinal vein occlusion</keyword>
  <keyword>Visual loss</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Statin</keyword>
  <keyword>Neovascularization</keyword>
  <keyword>Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

